共查询到20条相似文献,搜索用时 31 毫秒
1.
Dror Sayar MD PhD Yoav Burstein MD Bela Bielorai MD Amos Toren MD PhD Rina Dvir MD 《Pediatric blood & cancer》2010,55(1):183-185
Gemtuzumab ozogamicin (GO) is a humanized anti‐CD33 antibody used for treating patients with CD33+ acute myeloid leukemia (AML). We report three young children (two infants and one toddler) with AML treated with GO 9 mg/m2. Two received two doses at diagnosis alone with conventional chemotherapy and one received one dose after relapse. GO was well tolerated and all three achieved remission. All were transplanted: one relapsed after 5 months and died of disease, one died a toxic death in remission due to pulmonary fibrosis, and one survived (41 months from diagnosis). In conclusion, GO was well tolerated in these young patients with evidence for efficacy. Pediatr Blood Cancer 2010;55:183–185. © 2010 Wiley‐Liss, Inc. 相似文献
2.
Myeloid lineage switch following chimeric antigen receptor T‐cell therapy in a patient with TCF3‐ZNF384 fusion‐positive B‐lymphoblastic leukemia
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Matthew J. Oberley Paul S. Gaynon Deepa Bhojwani Michael A. Pulsipher Rebecca A. Gardner Matthew C. Hiemenz Jianling Ji Jennifer Han Maurice R.G. O'Gorman Alan S. Wayne Gordana Raca 《Pediatric blood & cancer》2018,65(9)
A pediatric patient diagnosed initially with B‐lymphoblastic leukemia (B‐ALL) relapsed with lineage switch to acute myeloid leukemia (AML) after chimeric antigen receptor T‐cell (CAR‐T) therapy and hematopoietic stem cell transplant. A TCF3‐ZNF384 fusion was identified at diagnosis, persisted through B‐ALL relapse, and was also present in the AML relapse cell population. ZNF384‐rearrangements define a molecular subtype of B‐ALL characterized by a pro‐B‐cell immunophenotype; furthermore, ZNF384‐rearrangements are prevalent in mixed‐phenotype acute leukemias. Lineage switch following CAR‐T therapy has been described in patients with KMT2A (mixed lineage leukemia) rearrangements, but not previously in any patient with ZNF384 fusion. 相似文献
3.
4.
5.
6.
7.
8.
9.
miR‐155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Ranjani Ramamurthy Maya Hughes Valerie Morris Hamid Bolouri Robert B. Gerbing Yi‐Cheng Wang Michael R. Loken Susana C. Raimondi Betsy A. Hirsch Alan S. Gamis Vivian G. Oehler Todd A. Alonzo Soheil Meshinchi 《Pediatric blood & cancer》2016,63(12):2096-2103
10.
Valerie de Haas MD PhD Ch. Michel Zwaan MD PhD Ursula Creutzig MD PhD Gertjan L. Kaspers MD PhD 《Pediatric blood & cancer》2016,63(8):1457-1460
We evaluated the in vitro glucocorticoid (GC) responsiveness of 117 pediatric acute myeloid leukemia cells by considering GC resistance, GC‐induced proliferation, and GC‐induced differentiation. None of the samples was highly GC sensitive, and only 15% were intermediately sensitive. GC‐induced differentiation was not observed, while GC‐induced proliferation was observed in 27% of the samples. Samples with French‐American‐British classification (FAB) type M5 or activating Fms‐like tyrosine kinase 3 (FLT3) mutations were significantly more prone to this phenomenon. Although we could not confirm this in our study, if induced proliferation in vitro is paralleled in vivo, GCs during consolidation may have adverse effects on minimal residual leukemic cells, which might increase relapse risk. 相似文献
11.
Frequent coexistence of RAS mutations in RUNX1‐mutated acute myeloid leukemia in Arab Asian children
Lika'a Fasih Y. Al‐Kzayer MD PhD Kazuo Sakashita MD PhD Mazin Faisal Al‐Jadiry MD Salma Abbas Al‐Hadad MD Le T.N. Uyen MD Tingting Liu MD Kazuyuki Matsuda PhD Jaafar M.H. Abdulkadhim MD Tariq Abadi Al‐Shujairi MD Zead Ismael I.K. Matti MD Janan Ghalib Hasan MD Hussam M. Salih Al‐Abdullah MD Toshi Inoshita MD Minoru Kamata MD Maher A. Sughayer MD Faris F. Madanat MD Kenichi Koike MD PhD 《Pediatric blood & cancer》2014,61(11):1980-1985
12.
Early mixed T‐cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Larisa Broglie Irene Helenowski Lawrence J. Jennings Kristian Schafernak Reggie Duerst Jennifer Schneiderman William Tse Morris Kletzel Sonali Chaudhury 《Pediatric blood & cancer》2017,64(9)
Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post‐HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T‐cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T‐cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T‐cell chimerism may warrant closer disease monitoring and consideration for early intervention. 相似文献
13.
14.
Nobuyuki Hyakuna Yoshiko Hashii Hiroyuki Ishida Katsutsugu Umeda Yoshiyuki Takahashi Masayuki Nagasawa Hiromasa Yabe Yozo Nakazawa Katsuyoshi Koh Hiroaki Goto Hiroyuki Fujisaki Kimikazu Matsumoto Harumi Kakuda Michihiro Yano Akio Tawa Daisuke Tomizawa Takashi Taga Souichi Adachi Koji Kato 《Pediatric blood & cancer》2019,66(10)
In the AML‐05 clinical trial conducted by the Japanese Pediatric Leukemia/Lymphoma Group from 2006 to 2010, children with high‐risk acute myeloid leukemia (HR AML) received allogeneic hematopoietic stem cell transplantation (allo‐HSCT) at first complete remission (CR1). The aim of this study was to investigate the impact of allo‐HSCT on the outcome of HR AML. Patients with either monosomy 7, 5q?, t(16;21), Ph1, FLT3‐ITD, or induction failure after the first course of chemotherapy were eligible for transplant. Of 53 children with HR AML, 51 received allo‐HSCT—45 in CR1, five in CR2, and one with non‐CR. t(8;21), t(9;11), and t(16;21) abnormalities were identified in eight, five, and four patients, respectively. The stem cell sources varied—bone marrow in 30 patients, peripheral blood in three, and cord blood in 18. The median follow‐up was 62 months. The overall survival (OS) rates at 3 years were 73% and 25% for patients who received transplant at CR1 and ≥CR2, respectively. Multivariable analysis showed that patients with chronic graft‐versus‐host disease (cGVHD) had better OS. This study supports that allo‐HSCT is a suitable treatment for HR AML in CR1. The favorable outcome associated with cGVHD indicates that a graft‐versus‐leukemia effect might be occurring. 相似文献
15.
16.
An overview of the potential strategies for NK cell‐based immunotherapy for acute myeloid leukemia
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Patients with acute myeloid leukemia (AML) have relatively low survival rates compared to patients with other pediatric cancers. Relapse is frequent with conventional treatment and is a major cause of morbidity and mortality. Natural killer (NK) cells offer an alternative approach to chemotherapy that combats relapse by substantially eradicating AML blasts. New methods for enhancing NK cell activation and expression of the activating ligand on target malignant cells will increase the likelihood of success with this approach. We review these latest discoveries in NK cell‐based therapy for AML and delineate recent advances in sensitizing AML cells to NK cell‐mediated immunosurveillance. 相似文献
17.
18.
19.
20.
Coexpression of Multiple ABC‐Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Stephan Bartholomae MD Bernd Gruhn MD Klaus‐Michael Debatin MD Martin Zimmermann Ursula Creutzig MD Dirk Reinhardt MD Daniel Steinbach MD 《Pediatric blood & cancer》2016,63(2):242-247